We identified 30,355 patients with HS; their characteristics are described in Table I (Table II) .
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We could not account for HZ vaccination in this analysis. Because of the low number of events in each group, we could not stratify risk of HZ by type of IS.
We conclude that risk of development of HZ infection among patients with HS is only slightly higher than among patients without HS. The risk however is still low, even with exposure to IS. Although the need for vaccination should be assessed for patients individually, those with HS generally may not require HZ vaccination, even with immunomodulation, before the age of 50 years. Disclosure: Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, and Asana Biosciences and has received honoraria.
The sponsor has had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Reprints not available from the authors. 1 This lymphoma has been called the oncologist's great imitator for its myriad presentations. 2 There are 2 subtypes: Western (classic), with predominantly cutaneous and central nervous system manifestations, and Asian, which presents as fulminant multiorgan failure. 3 The cutaneous presentation varies from purpura to irregular telangiectasias, tender erythematous patches and plaques, and vasculitis. This lymphoma is typically widely disseminated, 3 and presenting symptoms can be vague and highly variable. Diagnosis is often made postmortem. IVBCL is highly aggressive; with treatment, patients have an overall survival of ;30%. 4 The vast majority of literature about IVBCL is composed of single case reports, with 1 large cohort of 388 patients. 1 To further investigate the demographic profile and prognosis of patients with IVBCL, we examined data from the Surveillance, Epidemiology, and End Results program database (SEER-18) for patients with IVBCL diagnoses given during 1973-2014, yielding 140 patients. Data analysis was performed using paired t test and 2 tests, with P\.05 being significant. The median age of diagnosis of IVBCL was 67 (range 27-97) years. Our study, thus, confirms known estimates of average age of onset of this disease. However, while other reports document a male predominance, 1 we find no sex predilection. In this study, as expected, two thirds of patients with IVBCL diagnoses died (Fig 1) . However, only 60% of those patients died of their lymphoma. Other causes of death ranged widely, from cardiovascular disease to neurologic disease, infection, and chronic obstructive pulmonary disease (Table I) . There was no significant difference in time to death for IVBCL patients who died of their lymphoma versus those who died of other causes. Further, there was no significant difference in sex or race composition of those 2 groups. It is notable that the advent of rituximab revolutionized the treatment of B-cell lymphomas, including IVBCL. Fourteen patients in this cohort were given IVBCL diagnoses before the advent of rituximab in 1997. Overall probability of death was significantly higher during the prerituximab era (P\.04); we found a 5-year disease-specific survival of 53% for patients given IVBCL diagnoses in the postrituximab era. A review of the literature revealed overall survival rates of 38% before rituximab. 5 We found no significant difference in specific causes of death between the time periods, although the number of patients is small.
Our study highlights that although IVBCL is often fatal, 40% of patients who die with a diagnosis of IVBCL do so due to other potentially treatable causes. Clinicians must maintain perspective when treating these patients and ensure they are being treated appropriately for other comorbidities.
This study is limited because of its retrospective study design. Further analysis of cases with extensive clinical data will be necessary to further parse the question of management of disease and decreasing mortality in patients with IVBCL. 
